David Dai

Stock Analyst at UBS

(0)
# 4739
Out of 5,218 analysts
21
Total ratings
18.75%
Success rate
-20.67%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Immunocore Hldgs
Initiates Coverage On: Sell
24
28.93 -17.04% 1 Oct 24, 2024
Nuvalent
Initiates Coverage On: Neutral
100
86.68 15.37% 1 Oct 24, 2024
Blueprint Medicines
Initiates Coverage On: Neutral
88
93.28 -5.66% 1 Oct 24, 2024
Perspective Therapeu...
Initiates Coverage On: Buy
20
3.45 479.71% 1 Oct 24, 2024
Nurix Therapeutics
Initiates Coverage On: Buy
35
20.21 73.18% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
42.8 68.22% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
27
9.6 181.25% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
61.1 12.93% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
25.19 98.49% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
17
7.83 117.11% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
11.77 154.89% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
28.75 108.7% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
13.89 166.38% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.97 2786.6% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
14.61 173.79% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
3.2 1150% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
2.35 2027.66% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
37.26 39.56% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017